StockData
SOPHiA GENETICS SA logo

SOPHiA GENETICS SA (SOPH) company profile

SOPHNasdaqServices-Computer Processing & Data PreparationFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 20-F on Mar 3, 2026Score 4/30
$7.45+0.01 (+0.13%)

Close on Nov 17, 2026Market cap $510.22MP/E –Yield –

About SOPHiA GENETICS

Services-Computer Processing & Data Preparation, SIC 7374

SOPHiA GENETICS is a healthcare software company that develops a cloud-based analytics platform for data-driven medicine. Its core product, SOPHiA DDM, standardizes and analyzes complex genomic and multimodal health data for applications across oncology, rare diseases, cardiology, and neurology. The company also offers the Alamut interpretation software, the SOPHiA CarePath multimodal module, and biopharma solutions for clinical trials and companion diagnostics. Its customers include academic and community hospitals, reference and specialty laboratories, and biopharmaceutical firms.

Headquartered in Rolle, Switzerland, the company operates across 75 countries through a direct commercial presence in 60 countries and distributors in 50 countries. It serves more than 993 hospital, laboratory, and biopharmaceutical customers globally and has supported the analysis of approximately 2.3 million genomic profiles. The company maintains nine regional data centers located in Switzerland, France, the Netherlands, the United States, Canada, Brazil, Australia, and the United Arab Emirates.

Summary of the business section of SOPHiA GENETICS's latest annual report, written by StockData.

Company profile

Company

Legal name
SOPHiA GENETICS SA
Founded
2011
Headquarters
Rolle, V8
Address
La Piece, Ch-1180 00000
Phone
41 21 694 10 60
Employees
415, Dec 31, 2025
Industry
Services-Computer Processing & Data Preparation
Incorporated in
V8
Fiscal year ends
December 31
Auditor
PricewaterhouseCoopers SA, Lausanne, Switzerland

Stock & identifiers

Ticker
SOPH
Exchange
Nasdaq
IPO date
Jul 23, 2021
Shares outstanding
68M, Dec 31, 2025
Filer category
Accelerated filer<br>Emerging growth company
SEC CIK
1840706
FIGI
BBG011PFK7Q9
Share class FIGI
BBG011PFK8K3
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Jurgi CamblongExecutive Chairman, Director3,378,650
Ross MukenChief Executive Officer, Director880,391
Well Daan VanChief Legal Officer330,081
Zhenyu XuChief Scientific Officer537,493
Philippe MenuChief Medical Officer190,993
George CardozaChief Financial Officer326,726
Abhimanyu VermaChief Technology Officer166,887
Manuela ValenteChief People Officer206,210
Kevin PuylaertChief Sales Officer147,732
Kathy L. HibbsDirector90,742
Troy CoxDirector328,743
Didier HirschDirector240,220
Vincent OssipowDirector522,860
Jean-Michel CosseryDirector206,212
Tomer BerkovitzDirector–

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Jul 23, 2021
Offer price
$18.00
Securities offered
13,000,000
Gross proceeds
$234.00M
Exchange
Nasdaq
First trading day
Jul 23, 2021
First-day close
$16.76-6.9%
Lock-up ends (est.)
Jan 19, 2022

“The initial public offering price is $18.00 per ordinary share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 415 full-time equivalents (“FTE”) across 28 countries, of whom 308 were located in EMEA, 80 were located in North America, 14 were located in Latin America and 13 were located in Asia Pacific.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?